Ocular Hypertension Pipeline Analysis, 2025 By Delveinsight Santen Pharmaceutical, Nicox Ophthalmics, Inc., Allysta Pharmaceuticals, Qlaris Bio, Inc, Ripple Therapeutics, Laboratoires Thea, Ocular T

(MENAFN- GetNews)


"Ocular Hypertension Pipeline Analysis"DelveInsight's,“Ocular Hypertension - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The Ocular Hypertension pipeline includes over 50 prominent companies actively developing more than 75 therapies for the treatment of ocular hypertension, according to DelveInsight.

Ocular Hypertension Overview:

Ocular hypertension is a condition characterized by elevated eye pressure due to improper drainage of the aqueous humor, the clear fluid that maintains eye shape and supports ocular health. While most individuals with ocular hypertension do not experience noticeable symptoms or vision changes, the condition increases the risk of developing glaucoma, which can damage the optic nerve and lead to vision loss. Not everyone with ocular hypertension will develop glaucoma, but regular monitoring by an eye care professional is essential for early detection and effective management. Lifestyle factors such as diet and stress can affect eye pressure, though some patients may require medication or other treatments to control it. Early intervention helps protect vision and prevent long-term damage.

Intraocular pressure can rise due to either increased fluid production or reduced drainage within the eye. Several underlying conditions can disrupt normal aqueous humor outflow, leading to elevated pressure. For example, uveitis-an inflammation of the eye's middle layer-can impede fluid drainage. Pigment dispersion syndrome, where tiny pigment granules from the iris circulate and block the trabecular meshwork, and pseudoexfoliation syndrome, involving the buildup of microscopic protein fibers, can both obstruct fluid flow. Additional contributing factors include eye tumors, large cataracts, prior trauma or surgery, and certain medications such as corticosteroids. Chronic angle-closure, where the iris blocks the drainage angle, can further restrict outflow and elevate eye pressure.

Download our report @

"Ocular Hypertension Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ocular Hypertension Therapeutics Market.

Key Takeaways from the Ocular Hypertension Pipeline Report

• DelveInsight's Ocular Hypertension pipeline report highlights a dynamic landscape, featuring over 50 active companies developing more than 75 therapies for Ocular Hypertension.

• In December 2024, the FDA approved a generic latanoprost 0.005% ophthalmic solution from Gland Pharma Limited, indicated for lowering elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This generic has been confirmed as bioequivalent and therapeutically equivalent to the brand-name Xalatan.

• In June 2024, the FDA granted De Novo classification to Balance Ophthalmics' FYSX Ocular Pressure Adjusting Pump. This innovative, non-pharmacological device is designed to reduce IOP during sleep in adults with open-angle glaucoma. The system combines a compact pump with pressure-sensing goggles, offering a novel way to manage nighttime IOP fluctuations.

• Leading companies advancing the Ocular Hypertension treatment landscape include Santen Pharmaceutical, Nicox Ophthalmics, Allysta Pharmaceuticals, Qlaris Bio, Ripple Therapeutics, Laboratoires Thea, Ocular Therapeutix, Otsuka Beijing Research Institute, Alcon Research, AbbVie, Glaukos Corporation, MediPrint Ophthalmics, Ocuphire Pharma, and others.

• Promising pipeline candidates under development include Sepetaprost, NCX 470, QLS-111, H-1337, RTC-1119, among others.

Ocular Hypertension Pipeline Analysis

The Ocular Hypertension pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Ocular Hypertension Market.

• Categorizes Ocular Hypertension therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Ocular Hypertension drugs under development based on:

  • Stage of development

  • Ocular Hypertension Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Ocular Hypertension Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Ocular Hypertension Licensing agreements

  • Funding and investment activities supporting future Ocular Hypertension market advancement.

Request for a sample report @

Ocular Hypertension Emerging Drugs

• Sepetaprost: Santen Pharmaceutical

• NCX 470: Nicox Ophthalmics, Inc.

• QLS-111: Qlaris Bio, Inc.

• H-1337: Allysta Pharmaceuticals

• RTC-1119: Ripple Therapeutics

Ocular Hypertension Companies

Over 50 leading companies are actively developing treatments for ocular hypertension. Among them, Santen Pharmaceutical has a drug candidate that has reached the most advanced stage of development, preregistration.

DelveInsight's report covers around 75+ products under different phases of Ocular Hypertension clinical trials like

• Ocular Hypertension Late stage Therapies (Phase III)

• Ocular Hypertension Mid-stage Therapies (Phase II)

• Ocular Hypertension Early-stage Therapies (Phase I)

• Ocular Hypertension Pre-clinical and Ocular Hypertension Discovery stage Therapies

• Ocular Hypertension Discontinued & Inactive Therapies

Ocular Hypertension pipeline report provides the Ocular Hypertension therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Ocular Hypertension Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Ocular Hypertension Therapies and Key Ocular Hypertension Companies: Ocular Hypertension Clinical Trials and recent advancements

Ocular Hypertension Pipeline Therapeutic Assessment

. Ocular Hypertension Assessment by Product Type

. Ocular Hypertension By Stage

. Ocular Hypertension Assessment by Route of Administration

. Ocular Hypertension Assessment by Molecule Type

Download Ocular Hypertension Sample report to know in detail about the Ocular Hypertension treatment market @ Ocular Hypertension Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Ocular Hypertension Current Treatment Patterns

4. Ocular Hypertension - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Ocular Hypertension Late-Stage Products (Phase-III)

7. Ocular Hypertension Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Ocular Hypertension Discontinued Products

13. Ocular Hypertension Product Profiles

14. Ocular Hypertension Key Companies

15. Ocular Hypertension Key Products

16. Dormant and Discontinued Products

17. Ocular Hypertension Unmet Needs

18. Ocular Hypertension Future Perspectives

19. Ocular Hypertension Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Ocular Hypertension Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN02092025003238003268ID1110008890